A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness.
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Bipolar I disorders; Psychotic disorders; Schizophrenia
- Focus Therapeutic Use
- Acronyms ENLIGHTEN-Early
- Sponsors Alkermes plc
- 15 Aug 2018 Planned End Date changed from 1 Feb 2019 to 1 Nov 2019.
- 15 Aug 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Oct 2019.
- 14 Jun 2017 New trial record